Page 40 - Cell Line News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ProBioGen Licenses GlymaxX® Technology to AbbVie Search jobs ADCC-Enhancement for Innovative Therapies BERLIN, Germany, January 21, 2021 / B3C newswire / --ProBioGen AG has signed a commercial license agreement with AbbVie for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody-dependent cell-mediated cytotoxicity (ADCC). The proven GlymaxX ® technology for production of afucosylated proteins is universally applicable, simple and potent. The unique advantage of the GlymaxX ® technology is that a single GlymaxX ® modified cell line is sufficient to produce both,...

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials The modified vaccina virus Ankara (MVA) is an attenuated vaccinia virus that has been used as a vector in the already approved Adenovirus-MVA-based Ebola vaccine. A new preprint appearing on the bioRxiv* server reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that is causing the current coronavirus disease 2019 (COVID-19) pandemic. The MVA provides a vector platform for the rapid production of such ...

Hypoxia signaling pathway could lead to COVID-19 treatments Researchers in Spain have demonstrated that studying the hypoxia signaling pathway could provide opportunities for treating coronavirus disease 2019 (COVID-19). The team conducted a study showing that hypoxic (oxygen-deficient) conditions reduced the expression of host cell receptors for the causative agent – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hypoxic conditions reduced expression of angiotensin-converting enzyme 2 (ACE2) – the primary host cell receptor required for viral attachment and entry. They als...

The market is expected to grow with a CAGR of 6. 4% from 2020-2027. Increasing adoption of regenerative medicines, rising prevalence of cancer across the world, and increasing investments in R&D; by pharmaceutical and biotechnology companies are the key factors driving the growth of the North America cell line development serum market.New York, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Cell Line Development Serum Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Type ; By Application ; and Country" - ht...

New antibody discovery platform could help accelerate CAR-T therapeutic development In a paper published in the Journal of Biological Chemistry​​​, OXGENE scientists used the self-labelling integral membrane (SLIM) protein discovery system to identify a panel of novel antibodies against the oncogenic target epithelial cell adhesion molecule, which remained in its native configuration within the cell membrane. They said they were able to further demonstrate the functionality of these antibodies in killing cancer cells, when used as a targeting domain of CAR-T cells, thereby “validatin...